Blockchain Registration Transaction Record

Quantum BioPharma's Lucid-MS Targets MS Mobility Loss on BioMedWire Podcast

Quantum BioPharma featured on BioMedWire Podcast discussing Lucid-MS for MS mobility loss and unbuzzd(TM) alcohol metabolism product. Phase 2 trial upcoming.

This news matters because multiple sclerosis affects over 2.8 million people worldwide, and current treatments often fail to address mobility loss caused by nerve damage. Quantum BioPharma's Lucid-MS aims to fill this gap by targeting myelin degradation, potentially improving quality of life for patients. Additionally, the company's unbuzzd(TM) product offers a novel approach to alcohol metabolism, which could have broader public health implications. The upcoming Phase 2 trial will provide crucial data on Lucid-MS's efficacy, making this a pivotal moment for both the company and MS patients.